COMMUNIQUÉS West-GlobeNewswire

Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership
05/06/2025
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports that Omega Laboratories Inc. of Ohio, USA (“ [...]
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain
05/06/2025
Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports [...]
Tria Federal Promotes Atchut Kanthamani to President, Opens New Maryland Office
05/06/2025
ARLINGTON, Va., June 05, 2025 (GLOBE NEWSWIRE) -- Tria Federal has promoted Atchut Kanthamani to the new position of President. In this role, he will lead Tria's business growth and technology innovation teams. [...]
TOMI Announces Appointment of David Vanston as Chief Financial Officer
05/06/2025
FREDERICK, Md., June 05, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the appointment [...]
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
05/06/2025
HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced that it has been selected for inclusion in the [...]
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
05/06/2025
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed [...]
Biomerica’s inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology
05/06/2025
Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods ® IBS Test. Gastroenterology , the premier journal in gastrointestinal science, features data [...]
DIOSynVax Presents Its Technology at the Invitation-Only Next Venture Capital Unit (VCU) Health Tech Showcase at the London Stock Exchange
05/06/2025
CAMBRIDGE, United Kingdom and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing safe, innovative, broadly protective vaccines presented its [...]
Nanox Receives MDR CE Mark for HealthOST, an Advanced AI-Powered Software for Spine Assessment
05/06/2025
HealthOST identifies vertebral height loss and bone mineral density, which are key indicators of musculoskeletal disease Osteoporosis is a common progressive bone disease among adults over 50 years of age that causes [...]
Teladoc Health to Participate in Upcoming Investor Conference
05/06/2025
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Chuck Divita, chief executive officer, and Mala Murthy, chief financial officer, [...]
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
05/06/2025
CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2025
BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
05/06/2025
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing [...]
Annovis to Host Webinar and Live Q&A on June 24, 2025
05/06/2025
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as [...]
DiagnaMed Expands Clean Hydrogen Energy Extraction Capabilities to Demonstrate Proof of Concept of Proprietary Technology
05/06/2025
TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extraction technologies, [...]
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
05/06/2025
Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug [...]
Kestra Medical Technologies Announces Appointment of Conor Hanley to its Board of Directors
05/06/2025
KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an [...]
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
05/06/2025
LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., [...]
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
05/06/2025
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment options The multiple regulatory designations were [...]

Pages